生物活性

Pembrolizumab 派姆单抗是一种有效的、高选择性的、人源IgG4-kappa单克隆抗体，同时也是抑制剂，靶向PD-1，具有潜在的免疫检查点抑制活性和抗肿瘤活性。PD-1 与派姆单抗的结合位于 PD-1 的 C＇D 环上。MW：146.286 KD。

除了黑素瘤和肺癌，pembrolizumab在其他晚期实体肿瘤和恶性血液病中同样也具有疗效。Pembrolizumab具有在可接受范围的副作用，在具有晚期非小细胞肺癌的患者中，具有抗肿瘤活性

（Pembrolizumab 无法识别鼠类PD-1蛋白，需使用人源化小鼠或表达人PD-1基因的小鼠）

化学性质

参考文献

[1] Minan Wang, et al. FASEB J. Humanized mice in studying efficacy ａnd mechanisms of PD-1-targeted cancer immunotherapy

[2] Shuguang Tan, et al. Nat Commun. An unexpected N-terminal loop in PD-1 dominates binding by nivolumab

[3] Reck M, et al. N Engl J Med. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

[4] Faghfuri E, et al. Expert Rev Anticancer Ther. Nivolumab ａnd pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.

[5] Barbee MS, et al. Ann Pharmacother. Current status ａnd future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, ａnd nivolumab in oncology.

[6] Garon EB, et al. N Engl J Med. Pembrolizumab for the treatment of non-small-cell lung cancer.